Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1381, 2003-01, pp. : 17-17
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
FDA use of advisory committees not optimum
Inpharma, Vol. 1, Iss. 1570, 2007-01 ,pp. :
Access to resources
Recommend
US FDA issues not approvable letter for istradefylline.
Inpharma, Vol. 1, Iss. 1628, 2008-01 ,pp. :
Public misconceptions about FDA-approved drugs
Reactions Weekly, Vol. 1, Iss. 1372, 2011-01 ,pp. :
A US FDA advisory committee recommends that alosetron [`Lotronex'; GlaxoSmithKline] be reintroduced
Inpharma, Vol. 1, Iss. 1336, 2002-01 ,pp. :
The US FDA and the flow of health economics information
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 285, 2000-01 ,pp. :